&Partners’s iShares US Pharmaceuticals ETF IHE Stock Holding History

&Partners’s Portfolio IHE Stock Details IHE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$243K	Buy	+2,458	New	+$222K	﹤0.01%	2262
2025 Q2	–	Sell	-3,501	Closed	-$240K	–	2016
2025 Q1	$240K	Sell	3,501 -55	-2%	-$3.82K	﹤0.01%	1533
2024 Q4	$234K	Sell	3,556 -398	-10%	-$27.4K	﹤0.01%	1466
2024 Q3	$279K	Sell	3,954 -76	-2%	-$5.3K	0.01%	1136
2024 Q2	$267K	Buy	+4,030	New	+$264K	0.01%	752

Other funds holding IHE

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 57.61% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

IWS

Insight Wealth Strategies San Ramon, California $1.02B AUM 38% 1-Year Est. Return

&Partners's IHE Position: Q2 2026 in Review

&Partners opened a new position in iShares US Pharmaceuticals ETF (IHE) in Q2 2026: 2,458 shares worth $243K. The stake represents ﹤0.01% of the portfolio and ranks #2262 among its holdings. This is a return to the name: &Partners previously reported a position in IHE as recently as Q1 2025.

&Partners first reported a position in IHE in Q2 2024 and has held it in 5 quarters since. The position peaked at $279K in Q3 2024. 210 funds tracked by Wall St. Rank hold IHE as of Q2 2026.

&Partners held 2,458 shares of iShares US Pharmaceuticals ETF worth $243K as of Q2 2026.
iShares US Pharmaceuticals ETF was a new &Partners position in Q2 2026.
iShares US Pharmaceuticals ETF made up ﹤0.01% of &Partners's portfolio in Q2 2026, its #2262 holding.
&Partners first reported a position in iShares US Pharmaceuticals ETF in Q2 2024 and has held it in 5 quarters since.
&Partners's iShares US Pharmaceuticals ETF position peaked at $279K in Q3 2024.
210 funds tracked by Wall St. Rank held iShares US Pharmaceuticals ETF as of Q2 2026.

Based on &Partners's 13F filing for Q2 2026, filed 14 Aug 2026.